SurModics slashes delivery tech workforce, closes plant in restructuring

SurModics ($SRDX), which markets drug delivery technology, is laying off 9% of its workforce and bidding goodbye to the company's CFO and human resources chief in a reorganization spurred by the loss of a big customer. The Eden Prairie, MN-based operation says it will also close a manufacturing facility in Owings Mills, MD, consolidating that work back at its headquarters.

SurModics counted 215 people on its staff at the end of the year, meaning pink slips have been handed out to about 20 workers. The Minneapolis Star Tribune notes that the tech company has been hit by Johnson & Johnson's decision to stop making drug-coated stents. SurModics supplies the polymer coating for those stents.

"While a workforce reduction is always a very difficult decision, it was necessary to enable us to achieve our objectives," says CEO Gary Maharaj. "We thank our affected employees for their contributions and wish them well in their future endeavors."

- check out the SurModics release
- here's the report from the Star Tribune

Suggested Articles

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

GigaGen reported that its antibody treatment against COVID-19 was 100 times more protective than plasma and could be ready for human trials in 2021.

Seres Therapeutics is looking for a speedy approval of its once failed drug after it comes through a phase 3 test.